Acute Myocardial InfarctionNCT06281054
Acute Myocardial Infarction in Cancer Patients
An observational study of Acute Myocardial Infarction and Cancer, run by Samsung Medical Center at 1 site in South Korea.
Trial summary
Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Myocardial Infarction, Cancer
- What is being tested?
- Revascularization
- Type of treatment
- Surgery or procedure
- How many people
- 4,500,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Jan 2002to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who were diagnosed with cancer from 2002 to 2021 will be considered in the study. Among these patients, those diagnosed with acute myocardial infarction after the diagnosis with cancer will be included in the study.
Who may be able to join
- Patients diagnosed with cancer between 2002 and 2021
- Patients who were diagnosed with acute myocardial infarction after cancer diagnosis
Who cannot join
- Patients who died during period of cancer diagnosis
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Chonnam National University Hospital, Chonnam National University Medical School
Gwangju
About this study
Official title: Risk and Clinical Outcomes of Acute Myocardial Infarction in Patients With Cancer: A Nationwide Study
Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis.
Read the detailed description
This study will be conducted using Korean National Health Insurance Service database. Patients who were diagnosed with cancer from 2002 to 2021 will be included in the study. Using the selected patients, current study will analyze the incidence and prognosis of acute myocardial infarction in cancer patients and the prognosis according to the treatment method for acute myocardial infarction will be compared. Primary outcome will be all-cause death. Secondary outcomes will be myocardial infarction, revascularization, hospitalization for heart failure, stroke, and clinically relevant bleeding.
- Conditions
- Acute Myocardial Infarction, Cancer
- Being tested
- Revascularization
- Keywords
- Acute myocardial infarction, Cancer, Incidence, Prognosis
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RevascularizationProcedure or surgery
Performing PCI or CABG
| Study group | Role | What they receive |
|---|---|---|
| Revascularized Group | Cancer patients with diagnosis of acute myocardial infarction that was treated with PCI or CABG Receives: Procedure: Revascularization | |
| Medical Group | Cancer patients with diagnosis of acute myocardial infarction that was treated with medical treatment only |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause death
All-cause death which was obtained from death certification collected by Statistics Korea at the Ministry of Strategy and Finance of South Korea
Measured: 2-years after diagnosis of acute myocardial infarction
Secondary outcomes (5)
Myocardial infarction
Myocardial infarction is defined as presence of the diagnostic codes (ICD-10 I21, I22) in the primary position during hospitalization
Measured: 2-years after diagnosis of acute myocardial infarction
Revascularization
Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
Measured: 2-years after diagnosis of acute myocardial infarction
Hospitalization for heart failure
Heart failure events requiring hospitalization defined as presence of the diagnostic codes (I110, I130, I132, I255, I420, I425-I429, I43, I50, I971) in the primary position during hospitalization
Measured: 2-years after diagnosis of acute myocardial infarction
Stroke
Stroke is defined as ischemic stroke (ICD-10 I63, I64) or intracranial hemorrhage (ICD-10 I60-62), combined with the codes of diagnostic brain imaging.
Measured: 2-years after diagnosis of acute myocardial infarction
Clinically relevant bleeding
Bleeding requiring hospitalization or transfusion
Measured: 2-years after diagnosis of acute myocardial infarction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2024
- Study start1 Jan 2002
- Primary completion31 Dec 2021
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 4,500,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Chonnam National University
- Responsible party
- Principal investigator, Joo Myung Lee, Samsung Medical Center
- Investigators
- Joo Myung Lee, MD, MPH, PhD, Principal investigator, Samsung Medical CenterSeung Hun Lee, MD, PhD, Principal investigator, Chonnam National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06281054
- Sponsor's protocol ID
- SMC2023-12-027
- Status last verified
- Mar 2025
- First submitted
- 20 Feb 2024
- Last updated
- 14 Mar 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is National Health Insurance Data Analysis. Therefore, sharing the original patient-level data is not possible under regulation by the Korean government.
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk and Clinical Outcomes of Acute Myocardial Infarction in Patients With Cancer: A Nationwide Study
- ClinicalTrials.gov ID
- NCT06281054
- Acronym / sponsor ID
- SMC2023-12-027
- Conditions
- Acute Myocardial Infarction, Cancer
- Keywords
- Acute myocardial infarction, Cancer, Incidence, Prognosis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 4,500,000 participants (estimated)
- Lead sponsor
- Samsung Medical CenterUniversity, hospital or other
- Collaborators
- Chonnam National University
- Study start
- 1 Jan 2002 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 28 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis.
Detailed description
This study will be conducted using Korean National Health Insurance Service database. Patients who were diagnosed with cancer from 2002 to 2021 will be included in the study. Using the selected patients, current study will analyze the incidence and prognosis of acute myocardial infarction in cancer patients and the prognosis according to the treatment method for acute myocardial infarction will be compared. Primary outcome will be all-cause death. Secondary outcomes will be myocardial infarction, revascularization, hospitalization for heart failure, stroke, and clinically relevant bleeding.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Revascularized Group | – | Procedure: RevascularizationCancer patients with diagnosis of acute myocardial infarction that was treated with PCI or CABG |
| Medical Group | – | –Cancer patients with diagnosis of acute myocardial infarction that was treated with medical treatment only |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who were diagnosed with cancer from 2002 to 2021 will be considered in the study. Among these patients, those diagnosed with acute myocardial infarction after the diagnosis with cancer will be included in the study.
Key inclusion criteria (2 listed)
- Patients diagnosed with cancer between 2002 and 2021
- Patients who were diagnosed with acute myocardial infarction after cancer diagnosis
Key exclusion criteria (1 listed)
- Patients who died during period of cancer diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RevascularizationPerforming PCI or CABG | Procedure or surgery | Revascularized Group |
Primary outcome
All-cause death
Time frame: 2-years after diagnosis of acute myocardial infarction
All-cause death which was obtained from death certification collected by Statistics Korea at the Ministry of Strategy and Finance of South Korea
5 secondary outcomes
Myocardial infarction
Time frame: 2-years after diagnosis of acute myocardial infarction
Revascularization
Time frame: 2-years after diagnosis of acute myocardial infarction
Hospitalization for heart failure
Time frame: 2-years after diagnosis of acute myocardial infarction
Stroke
Time frame: 2-years after diagnosis of acute myocardial infarction
Clinically relevant bleeding
Time frame: 2-years after diagnosis of acute myocardial infarction
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2025.
- Individual participant dataSharing planned: No. This is National Health Insurance Data Analysis. Therefore, sharing the original patient-level data is not possible under regulation by the Korean government.
Related trials for Acute Myocardial Infarction
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joo Myung Lee, MD, MPH, PhD principal investigator
Samsung Medical Center
Seung Hun Lee, MD, PhD principal investigator
Chonnam National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction and Cancer, run by Samsung Medical Center at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All-cause death (time frame: 2-years after diagnosis of acute myocardial infarction). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2025.